Anirolac is a nonsteroidal anti-inflammatory drug. It is chemically related to ketorolac, and to tolmetin and indomethacin, approved nonsteroidal anti-inflammatory drugs marketed as antiarthritics but not as analgesics. Anirolac has shown both analgesic and anti-inflammatory actions in animal models. Anirolac is absorbed rapidly and completely after oral intake and has a plasma elimination half-life of about 2 hours in humans with normal renal function. Anirolac is a cyclooxygenase inhibitor and also inhibits platelet aggregation in vitro. Drowsiness is the most common side effect associated with anirolac. The pain relief provided by oral anirolac was slower to take effect, safe, and lasted longer than that provided by injectable morphine sulfate. It potentiated the GABA-antagonistic effects of the quinolones (norfloxacin, ciprofloxacin, enoxacin, and pipemidic acid).